Last updated: April 23, 2026
Who supplies irinotecan hydrochloride as an active pharmaceutical ingredient (API)?
The market for irinotecan hydrochloride APIs is concentrated in a small set of global manufacturers and specialty generic API producers, with supply routed through distributors and integrated CDMOs. Commercial availability typically spans:
- Synthetic API producers supplying irinotecan hydrochloride as bulk drug substance
- Contract manufacturers producing intermediate-heavy routes and finishing API to customer specifications
- Wholesalers/distributors sourcing from API producers and re-selling to finished-dose manufacturers and compounding channels
Which countries dominate supply for irinotecan hydrochloride API?
Supply is dominated by established small-molecule API hubs in:
- India
- China
- Europe (limited but present for certain grade and regulatory status)
What finished-dose manufacturers use irinotecan hydrochloride supply?
Finished-dose supply chains for irinotecan depend on whether a company sources:
- Commercial bulk API directly, or
- Partnered API through a specialty importer/distributor, then formulates and packages
This typically includes multinational oncology brands and generic manufacturers in oncology-focused portfolios.
What supply channels exist for buyers of irinotecan hydrochloride?
Procurement typically falls into four practical routes:
- Direct from API manufacturer (for volume and qualification readiness)
- Through a registered distributor/wholesaler (for faster lead times and lot availability)
- Through a CDMO that offers API + fill-finish integration (for validated workflow and controlled change management)
- Via tender frameworks used by hospital procurement organizations for finished product, then mapped back to upstream API sources
Key supplier selection criteria for irinotecan hydrochloride
For oncology APIs, buyers typically screen suppliers on:
| Criterion |
What buyers verify |
| Regulatory status |
DMF/EDMF filing status, CEP availability where applicable |
| GMP readiness |
Sterile-adjacent controls are not required for API, but GMP for small-molecule API is mandatory |
| Analytical package |
Full release and stability methods, compendial coverage, impurity profiling |
| Supply continuity |
Multi-source qualification and lead-time reliability |
| Change control |
Notification timelines for synthesis, purification, or analytical method changes |
| Packaging and transport |
Controlled storage conditions, tamper evidence, traceability |
What are typical product specifications buyers request for irinotecan hydrochloride?
Commercial API specifications usually include:
- Identity and assay (irinotecan hydrochloride content)
- Impurity limits (process-related impurities and degradation products)
- Water/solvent residues where applicable to route
- Particle and bulk density (for consistent downstream formulation performance)
- Microbiology (API level requirements per relevant GMP and regional expectations)
- Stability program and shelf-life assignment based on real-time and accelerated data
How do suppliers differ by grade (commercial vs. qualified for regulated markets)?
In practice, buyers distinguish between:
- Commercial grade for lower-stringency channels
- Regulatory-grade API for markets that require DMF/EDMF/CEP and formal qualification by finished-dose manufacturers
What buyers should do to confirm actual supplier fit
Procurement teams usually require the supplier to provide:
- A current certificate of analysis (CoA) for representative lots
- Specification sheet aligned to intended regulatory target
- DMF/EDMF references or equivalent documentation where required
- Stability and impurity profile support for qualification packages
- Manufacturing site GMP evidence (and audit readiness)
Key Takeaways
- Irinotecan hydrochloride supply is concentrated among specialized small-molecule API producers and distributors, with dominant production in India and China plus limited European participation.
- Supplier qualification hinges on regulatory documentation (DMF/EDMF/CEP), analytical package depth, and change-control stability tied to impurity and process consistency.
- Buyers typically source via direct API manufacturing, registered distribution, or integrated CDMO models depending on volume, qualification timelines, and packaging/analytical needs.
FAQs
1) Can a buyer source irinotecan hydrochloride API from distributors instead of manufacturers?
Yes. Many buyers use registered distributors/wholesalers for quicker lot access while manufacturers handle upstream supply and DMF documentation.
2) Which documentation matters most when qualifying an API supplier for regulated markets?
Qualification typically centers on DMF/EDMF/CEP availability, specification alignment, and full analytical release and stability documentation.
3) Do suppliers provide CoAs and impurity profiles for irinotecan hydrochloride?
Qualified suppliers routinely provide CoA for release and support impurity profiling as part of the analytical package.
4) What drives lead time for irinotecan hydrochloride API supply?
Lead time is driven by API availability by lot, synthesis campaign schedules, and finished-dose customer qualification status.
5) Is irinotecan hydrochloride considered a high-compliance API supply category?
Yes. It is an oncology API where buyers place emphasis on GMP documentation, impurity control, and change management for downstream consistency.
References
- U.S. FDA. Drug Master Files (DMF) database and guidance. (Accessed via FDA resources).
- European Medicines Agency (EMA). European Drug Master File (EDMF) framework and documentation. (Accessed via EMA resources).
- European Directorate for the Quality of Medicines (EDQM). CEP framework and public information. (Accessed via EDQM resources).
